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Background: Bilirubin is a highly-hydrophobic tetrapyrrole which binds to plasma
albumin. It is conjugated in the liver to glucuronic acid, and the water-soluble glucuronides
are excreted in urine and bile. The membrane transporters of bilirubin diglucuronide
are well-known. Still undefined are however the transporters performing the uptake of
bilirubin from the blood into the liver, a process known to be fast and not rate-limited.
The biological importance of this process may be appraised by considering that in normal
adults 200–300mg of bilirubin are produced daily, as a result of the physiologic turnover
of hemoglobin and cellular cytochromes. Nevertheless, research in this field has yielded
controversial and contradicting results. We have undertaken a systematic review of the
literature, believing in its utility to improve the existing knowledge and promote further
advancements.
Methods: We have sourced the PubMed database until 30 June 2017 by applying
5 sequential searches. Screening and eligibility criteria were applied to retain research
articles reporting results obtained by using bilirubin molecules in membrane transport
assays in vitro or by assessing serum bilirubin levels in in vivo experiments.
Results: We have identified 311 articles, retaining 44, reporting data on experimental
models having 6 incremental increases of complexity (isolated proteins, membrane
vesicles, cells, organ fragments, in vivo rodents, and human studies), demonstrating the
function of 19 membrane transporters, encoded by either SLCO or ABC genes. Three
other bilirubin transporters have no gene, though one, i.e., bilitranslocase, is annotated
in the Transporter Classification Database.
Conclusions: This is the first review that has systematically examined the membrane
transporters for bilirubin and its conjugates. Paradoxically, the remarkable advancements
in the field of membrane transport of bilirubin have pointed to the elusive mechanism(s)
enabling bilirubin to diffuse into the liver as if no cellular boundary existed.
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INTRODUCTION
Bilirubin (BR) is a tetrapyrrolic pigment found in plasma as an albumin-bound reversible complex
(Jacobsen and Brodersen, 1983). It derives from catabolism of heme, released by both hemoglobin
(75%) and cytochromes (25%), with a daily production of about 200–300mg in a normal adult
(Levitt and Levitt, 2014). The liver is the organ where BR is taken up, metabolized by glucurono-
conjugation, and excreted into the bile (Sticova and Jirsa, 2013).
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In the liver, the membrane transport mechanisms of BR have
distinctive features, depending on the BR molecule (conjugated
or not), the plasma membrane interface (vascular or biliary), and
the bioenergetics of transport (to electrochemical equilibrium or
not).
Considering sinusoidal uptake of BR, the liver has the capacity
to take up as much as 50% of a BR load in a single pass (Stollman
et al., 1983) by a process that shows substrate saturation and
competitive inhibition by other organic anions, like indocyanine
green and bromosulfophthalein (BSP) (Hunton et al., 1961;
Scharschmidt et al., 1975; Bloomer and Zaccaria, 1976). This
is evidence for a transporter-mediated process. Considering
transport of conjugated BR from the liver parenchyma to the
bile, it is rate-limiting, not inhibited by BR (Goresky, 1965), and
energy-dependent (Nakatani et al., 1995).
Genetic diseases have shed light on the membrane
transporters for BR and its conjugates (Erlinger et al., 2014;
Keppler, 2014) The Dubin-Johnson syndrome is caused by
mutations in the protein MRP2, encoded by ABCC2, which
drastically reduce the capacity of the liver to excrete the
conjugated pigment into the bile. The sister protein MRP3,
encoded by ABCC3, is expressed at the sinusoidal membrane
and pumps bilirubin diglucuronide (BDG) back into the blood,
which leads to conjugated hyperbilirubinaemia. Rotor syndrome
is characterized by defective reuptake of BDG from the blood
into the liver by OATP1B1/OATP1B3, encoded by SLCO1B1/1B3
(Keppler, 2014) and is known as a predominantly conjugated
hyperbilirubinemia.
The Gilbert’s syndrome is characterized by familial
unconjugated hyperbilirubinemia, due to UGT1A1 mutations
causing defective conjugation of BR with glucuronic acid in the
liver. However, defects of hepatic uptake transporters might
contribute to pathogenesis, as pointed out in a study on subjects
displaying the Gilbert’s syndrome but no UGT1A1 mutations
(Skierka et al., 2013).
Technical, biological and conceptual issues have contrasted
the progress of knowledge about the transporter-mediated
diffusion of unconjugated bilirubin (UCB) across biological
membranes. These are the insolubility and instability of BR
in aqueous media (McDonagh, 2008), the very fast rate of
transport (Billing and Black, 1969), the property of organic
anion transporters, such as OATPs, to handle a large number
of different drugs, metabolites or phytochemicals (Hagenbuch
and Stieger, 2013) and, not least, a steady confidence in the
occurrence of a single transporter protein performing this task.
Yet, transfer of BR across biological membranes remains one
of the fundamental questions of cellular biology, at the basis of
our understanding of the clinical biomarker bilirubinemia (Wang
et al., 2006; Levitt and Levitt, 2014). The central question is
about what makes it possible for the liver to take up 0.13–0.2mg
BR min−1.
Normal fluctuations of bilirubinemia have gained momentum
because mild increases are related to reduction of cardiovascular
disease risk, type-2 diabetes mellitus and other conditions
(Kapitulnik and Maines, 2012). Thus, it would be important
to understand if membrane transporters may participate in
these beneficial fluctuations, if they transport other endogenous
metabolites, or plant secondary metabolites that are in our diet,
or drugs, or if they can be targeted by time-dependent protein
reagents resulting in up- or down-regulation, and so many other
questions that other systems have already successfully addressed.
We recognized that a comprehensive review on BR-specific
membrane transporters is missing in the literature. In the attempt
to fill this deficit, we have undertaken a systematic review
of the literature, believing in its utility to both improve the
existing knowledge and promote a rational planning of new
investigations.
We addressed some fundamental research questions, common
to any experimental study about membrane transport, such as the
following.
What Transporters Catalyze Translocation
of Bilirubin across Biological Membranes?
This was a primary research question and one of the criteria for
eligibility.
What Experimental Model Was Used to
Assess Bilirubin Transport, Either in Vivo or
in Vitro?
It is important to have a survey of the methods used and
the related results, possibly independently obtained by different
research groups. It is a question relevant for the case of the
reproducibility, usability and predictability of available research
results. We searched for protein, vesicles/liposomes, isolated cells,
tissue fragments, isolated organs, in vivo animals, and clinical
trials.
What Bilirubin Molecule Was Used in
in Vitro Assays?
This was a primary research question and one of the criteria
for eligibility. Both BR and its conjugated derivatives were
considered, because both are transported by transporter-
mediated mechanisms.
What Bilirubin Concentrations Were Used
in Transporter Activity Assays?
The concentration conditions selected for the in vitro studies
were clearly relevant for the quality of the data, not only because
an assay that used physiological concentrations of transport
substrate or modulator had a higher predictability power, but also
because of chemical stability of BR.
Was Bilirubin Used as a Substrate or as a
Modulator of Transporter Activity?
Direct analysis of a transport substrate is the preferred approach
in any assay. However, the poor water solubility of BR (i.e., the
albumin-free, unconjugated species), its relevant physiological
concentration in the nM range, and its time-dependent chemical
decay limit the versatility of BR-based transport assays. By
exploiting the principles of inhibition kinetics, it is possible to
use an alternate transport substrate in the presence of BR as a
transporter modulator (typically a competitive inhibitor) and so
to estimate the properties of the transporter-BR interaction(s).
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What Competing Molecules Interfere with
Bilirubin Transporters?
Knowledge of the molecules competing with BR for membrane
transport sheds light on both fundamental aspects of BR
metabolism and its value as a serum biomarker. Furthermore,
this question concerns methodological issues, since some of
these competing molecules might be used in activity assays of
BR-specific membrane transporters.
MATERIALS AND METHODS
We have implemented the PRISMA guidelines to retrieve, select
and analyze primary research articles reporting results on BR
membrane transporters (Shamseer et al., 2015).
Identification of Articles in Public Database
Information Sources
We have chosen to search only PubMed, because it is the
benchmark repository of biomedical literature. Though it can be
considered that different databases have different algorithms to
process queries and apply filters, this review has disregarded the
point of managing, comparing and discussing differences in the
performance of search process among different databases.
We searched PubMed in four sequential search steps, as
described in Table 1.
Search Strategy
The time window was open, with the first paper dated 1970–
June 2017. Filters were not applied. The term transporter was
chosen because it is a standard term that defines a protein entity
associated with membrane transport function, corresponding to
theMeSHHeadingMembrane Transport Proteins (U.S. National
Library of Medicine).
The output of each search step was a set of automatically
identified articles. The second, third and fourth searches
contained duplicate articles that were immediately removed. The
fifth search was manual.
Selection of Eligible Articles
Selection Strategy
The articles identified by the sequential search steps were selected
by reading the abstract and/or the full text. Criteria for retaining
(IN) or discarding (OUT) are detailed in Table 2. As a result of
screening, selected articles underwent a more stringent eligibility
check, which retained articles eligible for the analysis and
classification of their study features.
RESULTS
Literature Search and Selection
Figure 1 shows the literature search strategy and the results
obtained at each of the five steps of the selection process.
The 1st search identified 149 article titles. Screening and
eligibility check enabled to include 24 articles in the review.
After this first step, we realized the limitations of the search
query, since some of the seminal papers on BR membrane
transport were not present among identified records (e.g.,
Stremmel et al., 1983; Cui et al., 2001; Briz et al., 2003). Therefore,
we decided to perform a sequence of query-based searches, in
order to refine our search strategy and possibly retrieve missing
articles.
In the 2nd and 3rd search phases (Figure 1), the term
“transporter” was substituted with either “carrier protein,” a
popular term in pre-genomic times, or the more restrictive term
“organic anion transporter.” We retrieved 158 and 78 records,
respectively, but only 2 were included in the final analysis.
Nevertheless, some classic papers were still missing (Cui et al.,
2001; Briz et al., 2003), raising the concern that some others
might have been left behind.
The 4th search phase was more straightforward, using the
names of BR membrane transporter proteins described in
previously retrieved articles, such as OATP, MRP, MDR or
bilitranslocase. It identified 215 articles, of which 14 were
included in the review.
The last phase was the manual retrieval of some articles that
escaped the prior searches. There is no obvious reason why two
articles (Cui et al., 2001; Briz et al., 2003), which are considered
milestones in transporter-mediated BR uptake and determined a
consolidated consensus on the role of OATP1B1 and OATP1B3
in hepatic BR uptake (Stieger and Hagenbuch, 2014), could not
be retrieved, in spite of the fact that their MESH terms listed both
“transporter” and “bilirubin.” Similarly, other papers using BR
and its conjugates as a transport substrate in accurate biochemical
studies (Jedlitschky et al., 1997; Kamisako et al., 1999; Pascolo
TABLE 1 | Search strategy.
# Search Rationale
1st Bilirubin AND membrane AND transporter
AND assay
Bilirubin is the tested molecule used in biological assays that measure the activity of a given membrane
transporter.
2nd Bilirubin AND membrane AND carrier
protein AND assay
Search #2 is the same as search #1, except for using the once popular MESH term Carrier protein instead of
Transporter.
3rd Bilirubin AND membrane AND organic
anion transporter AND assay
Search #3 is the same as search #1, except for using the MESH term Organic Anion Transporter instead of
Transporter. Organic anions include bilirubin.
4th OATP OR MRP OR MDR OR
bilitranslocase AND bilirubin AND assay
Search #4 is a query of articles reporting bilirubin-based biological assays of transporters identified by
search#1 (i.e., OATP OR MRP OR MDR OR bilitranslocase).
5th Manual Retrieval of articles that have escaped query-based searches, in spite of being indexed by MeSH terms such
as “transporter” and “bilirubin”.
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TABLE 2 | Selection strategy.
Phase Text In Out Results
Screening Abstract (with Materials
and Methods, if
needed)
• Primary/original research articles
• Using mammalian experimental models for
studying membrane transporters
• Using bilirubin
• Not in English
• Reviews
• Not performed in mammalian models
• Not using mammalian genetic material
• Not reporting results on bilirubin analysis
in biological or physiological fluids
• Not reporting results on biological
transport assays
Articles screened for further
eligibility check
Eligibility check Full text • The article section “Materials and Methods”
describes: (a) a biological assay to assess
membrane transport activity using bilirubin
as either substrate or modulator; (b)
chemical analysis of bilirubin in bio-fluids or
tissue extracts.
• The article section “Results” (including
Figures and Tables) reports experimental
data about transport and distribution of
bilirubin in compartments separated by
biological membranes.
• Bilirubin transport was just hypothesized
on the basis of existing literature
• Bilirubin was tested as inducer of the
expression of membrane transporters,
without experimental proof of change in
bilirubin transport activity or distribution
in compartments
• Mutated forms of membrane
transporters were tested, without
experimental proof of change in bilirubin
transport activity
Included articles as eligible
for the analysis of their study
features (STEP 3 of the
systematic review)
FIGURE 1 | Flowchart of the results of the literature search strategy and implementation of inclusion criteria. Four query-based searches and a manual one resulted in
the inclusion of 44 articles.
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et al., 2001; Rigato et al., 2004) remained out. Other articles,
reporting in vivo studies with drug transporter-deficient mouse
models with hypebilirubinemic phenotypes (Chen et al., 2008;
Lu et al., 2008) were lost but, in these cases, their MeSH terms
did not mention BR, which was a constitutive element of all
search queries of this review. The approach to manually retrieve
these articles was to check the list of references of the included
articles, or of reviews on drug and BR transporters. The manual
retrieval of articles was however kept to the least possible extent,
even if this implied the risk of overlooking some articles. In
fact, manual retrieval is neither systematic nor automatic, i.e.,
it is not reproducible, since it stems from individual experience,
curiosity or perspicacity. By contrast, this review aims at offering
a universal “baseline” of current knowledge on BR membrane
transporters and a method to update it and so measure the future
progress in the field.
Features of Bilirubin Membrane Transport
Studies
The 44 papers to be analyzed were then classified in two groups—
in vitro and in vivo studies, according to the experimental model
used to study BR transport. These studies are briefly described
below, with limited reference to other items of literature.
In Vitro Studies on Membrane Transport of
Bilirubin
The list of in vitro transport studies is reported in Table 3. Assays
used BR molecules either as transport substrates or as transport
modulators added to the assay mixture containing dyes, drugs or
metabolites. The dye sulfobromphthalein (BSP), used in hepatic
functional tests (Burra and Masier, 2004), has been applied in
pioneering pharmacokinetic experiments that demonstrated the
capacity of BR to inhibit BSP clearance in rats (Scharschmidt
et al., 1975).
Studies with Bilirubin as Substrate in Uptake Studies
The earliest attempts at identifying the membrane transporter
mediating the uptake of BR into the liver include a study (Wolkoff
and Chung, 1980) on a BSP-binding membrane protein, named
Organic Anion Binding Protein (OABP). It was isolated from rat
liver sinusoidal plasma membrane vesicles and the direct binding
with BR was measured by fluorescence spectrometry, which
led to the estimation of its dissociation constant Kd = 20µM.
Further cloning studies clarified that this protein was identical
to a segment of the β-subunit of F1-ATPase (Goeser et al.,
1990), which is well-known to have an extra-mitochondrial
localization (Mangiullo et al., 2008). A dimeric BSP- and
bilirubin-binding glycoprotein (BBBP) was also isolated from rat
liver plasma membranes, considered to be probably related to
OABP (Stremmel et al., 1983), but distinct from a third BR- and
BSP-binding protein known as bilitranslocase (BTL) (Tiribelli
et al., 1978). An antibody targeting BBBP inhibited the cellular
uptake of BR, BDG, and BSP in the human hepatoma cell line
HepG2, confirming the transporting function of this membrane
protein (Stremmel and Diede, 1990), and its distinct nature from
bilitranslocase (Torres et al., 1993).
The discovery of the cDNA encoding for Organic Anion
Transporting Polypeptides (Jacquemin et al., 1994) opened the
possibility to investigate the transport properties of members
of this superfamily of solute transporters. A study (Cui et al.,
2001) showed that [3H]BR could be transported into human
embryonic kidney cells (HEK293) stably transfected with OATP2
(OATP1B1), but not with OATP8 (OATP1B3). The apparent Km
was calculated to be 160 nM. OATP1B1-mediated transport of
BR was inhibited by BSP. These results were however questioned
after assessing uptake of [3H]BR into HeLa cells expressing
OATP2 (i.e., OATP1B1) (Wang et al., 2003), showing that it
was not different from uptake in control cells. Yet, the same
transfected cells performed a marked and specific increase in
uptake of BSP. It was deduced that the data reported by Cui
et al. should be ascribed to unspecific binding of [3H]BR on
the cell membrane(s) (Wang et al., 2003). However, specific
uptake of [3H]BR intoXenopus oocytes expressingOATP1B1 and
OATP1B3 was also reported (Briz et al., 2003).
A more recent study (Chu et al., 2015) explored the possibility
to measure uptake of [3H]BR (40 nM) into HEK293 cells stably
transfected with cynomolgus OATP1B1 and OATP1B3. Though
uptake of [3H]BR was measurable, uptake activity was too low to
use this kind of assay to kinetically characterize BR transport or
to screen transporter-drug interactions.
Another study was done on cultures of human
adenocarcinoma cell line (HepG2). BR was added to the
extracellular medium at 50 nM and its uptake into the cell
monolayer was followed for 1.5min by sampling and measuring
the pigment via thermal lens spectrometry (Passamonti et al.,
2005b), which exploits the thermal lens property of the pigment
in solution to estimate its concentration (Franko, 2008). This
analytical approach enabled to measure the progress of transfer
of BR from the albumin-free medium to the cell monolayer,
showing a time pattern similar to that recorded in perfused rat
livers (Stollman et al., 1983). The study showed that a polyclonal
antibody targeting an extracellular domain of a membrane
protein bilitranslocase (Battiston et al., 1998) nearly abolished
the cellular uptake of BR.
Studies with Bilirubin as Substrate in Efflux Studies
Besides the significance of BR uptake mechanisms, cellular
eﬄux mechanisms that favor the extrusion of BR have a
fundamental importance in utero. In facts, BR formed during
fetal development is transferred to thematernal circulation across
the cellular barrier provided by the placental trophoblast.
MRP1 is expressed at the level of the human placenta where it
pumps a variety of xeno- and endobiotics back to the maternal
blood (St-Pierre et al., 2000). It was identified as the most
likely player in eﬄux of BR from cultured human trophoblast
cells (BeWo cell line) used as a model of human placenta
(Pascolo et al., 2001). Eﬄux occurred at the apical side, which
is in contact with maternal blood. This study also assessed the
kinetics of BR uptake into these cells, finding that it was not
inhibited by taurocholate, a standard substrate of OATPs. Thus,
the trophoblast cellular barrier ensures the transfer of BR from
the fetal to the maternal circulation. The kinetic details of MRP1-
dependent BR transport were obtained in a study using plasma
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TABLE 3 | Features of included articles reporting in vitro studies.
References Experimental model
description
Bilirubin molecule [Bilirubin] Bilirubin-
transporter
interaction
Competing
substance
Transporter Search #
Wolkoff and
Chung, 1980
Protein isolated from rat liver
plasma membrane
Bilirubin 1.5–20µM Substrate BSP OABP 1st
Stremmel et al.,
1983
Rat liver plasma membrane
vesicles
Bilirubin 0.2–8µM Substrate BSP Not defined—55
kDa membrane
protein
2nd
Adachi et al.,
1990
Rat liver plasma membrane
vesicles
bis-glucuronosyl
bilirubin, bilirubin
50µM Substrate;
modulator
Bilirubin; BSP Unknown 1st
Passamonti and
Sottocasa, 1990
Rat liver plasma membrane
vesicles
Bilirubin 8–40 nM Modulator BSP bilitranslocase 1st
Stremmel and
Diede, 1990
HepG2 cells
(human hepato-carcinoma)
bis-glucuronosyl
bilirubin
4–48µM Substrate BSP Not defined—55
kDa membrane
protein
2nd
Passamonti
et al., 1997
Rat liver plasma membrane
vesicles
Bilirubin 2–20 nM Modulator BSP bilitranslocase 1st
Jedlitschky
et al., 1997
Plasma membrane vesicles
from HeLa, HeLa-MRP1
and HepG2 cells; canalicular
membrane vesicles from
livers of normal Wistar rats
and from Mrp2-deficient
GY/TR– mutant rats
Mono-and
bis-glucuronosyl
bilirubin
0.5µM Substrate Leukotriene C4 MRP1, MRP2, mrp2 5th
Kamisako et al.,
1999
Membrane vesicles from
HEK293 stably expressing
rat or human MRP2
[3H] Mono-and
bis-glucuronosyl
bilirubin
0.5µM Substrate Leukotriene C4,
17b-glucuronosyl
estradiol,
cyclosporin A
MRP2, mrp2 5th
(König et al.,
2000)
HEK293 stably expressing
OATP1B1
Mono-glucuronosyl
bilirubin
80 nM Substrate OATP1B1 1st
(Cui et al., 2001) HEK293 permanently
expressing OATP1B1 or
OATP1B3
[3H] Bilirubin, [3H]
Mono- and [3H]
Bis-glucuronosyl
Bilirubin
1µM Substrate BSP OATP1B1,
OATP1B3
5th
Pascolo et al.,
2001
BeWo cells
(human placental
trophoblast)
[3H] Bilirubin 5–100 nM Substrate BSP,
indomethacin,
taurocholate,
MK571
MRP1, MRP5 5th
Wang et al.,
2003
HeLa and HEK293 cells
expressing OATP1B1
Bilirubin 1µM Substrate OATP1B1 4th
Briz et al., 2003 Xenopus laevis oocytes
expressing OATP1B1 or
OATP1B3
[3H] Bilirubin 0–260 nM Substrate OATP1B1,
OATP1B3
5th
Bilirubin 100µM Modulator 17β-D-
glucuronosyl
oestradiol
OATP1B1,
OATP1B3
Lee et al., 2004 Membrane vesicles from
MDCKII stably expressing
MRP3
Mono-and
bis-glucuronosyl
bilirubin
12 nM (MGB),
9.5 nM (BGB)
Not characterized MRP3 1st
Rigato et al.,
2004
Membrane vesicles from
MDCKII and MDCKII stably
expressing MRP1 and
MRP2
[3H] Bilirubin 6–72 nM Substrate MRP1, MRP2 5th
Bilirubin 100 nM Modulator Leukotriene C4 MRP1, MRP2
Passamonti
et al., 2005b
HepG2 cells Bilirubin 50 nM Substrate Nicotinic acid,
BSP
bilitranslocase 1st
Calligaris et al.,
2006
Primary mouse embryo
fibroblasts from wild type
and Mrp1 (–/–) mice
Bilirubin 4–140 nM Substrate Mrp1 4th
(Continued)
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TABLE 3 | Continued
References Experimental model
description
Bilirubin molecule [Bilirubin] Bilirubin-
transporter
interaction
Competing
substance
Transporter Search #
Maestro et al.,
2010
Ea.hy926 cells
(human vascular
endothelium)
Bilirubin 50 nM Modulator Quercetin bilitranslocase 1st
Nakanishi et al.,
2012
Sandwich-cultured rat
primary hepatocytes
Bilirubin 20µM,
50µM
Modulator CDF (5-(and 6)-
carboxy-2′,7′-
dichlorofluorescein)
MRP2 1st
Terdoslavich
et al., 2012
Human and rat liver
precision-cut slices
Bilirubin 50 nM Modulator BSP Bilitranslocase 1st
Chu et al., 2015 HEK293 cells expressing
cynomolgus OATP1B1 and
OATP1B3
[3H] bilirubin 40 nM Substrate Rifampin OATP1B1,
OATP1B3
1st
Matsushima
et al., 2017
Inside-out rat erythrocyte
membrane vesicles
bilirubin 10µM Substrate 2,4-dinitrophenyl-
S-glutathione
MRPs 1st
Washed rat erythrocytes
membrane vesicles prepared from human cells transfected with
MRP1 (Km = 10 nM and Vmax = 100 pmol min−1 mg−1 of
protein) (Rigato et al., 2004). To characterize the role of Mrp1
in cellular eﬄux of BR and its protective effect against BR-
induced cytotoxicity, mouse embryo fibroblasts from either wild
type or Mrp1 knockout mice were used as a model (Calligaris
et al., 2006). After 4 h of exposure, [3H]BR accumulated more
in Mrp1−/− than in wild type fibroblasts, under all conditions
(40, 80 and 140 nM). Cellular ATP levels decreased in Mrp1−/−
cells but not in normal cells. BR (20–160 nM) was increasingly
cytotoxic in both cell lines, with a stronger effect in mutant cells.
Studies with Bilirubin as Modulator
The effect of BR as modulator of transporter activity has
been tested in several assays with model substrates, thus
circumventing the technical difficulties of analysing BR at very
low concentrations (<0.1µM) and yet taking advantage of
detailed kinetic analysis of transporter-BR interaction. Using
sinusoidal rat liver plasmamembrane vesicles, BR (50 or 100µM,
added at pH 7.8) was shown to inhibit BDG transport (Adachi
et al., 1990) or BSP transport (Passamonti and Sottocasa, 1990).
A complex experiment, aimed at quantitatively assess the
power of BR to protect from time-dependent inhibition of
bilitranslocase caused by the serine-specific reagent PMSF,
enabled to obtain an apparent dissociation constant (Kd =
2.1 nM) of the bilitranslocase-BR complex (Passamonti et al.,
1997). The same kinetic method was used to characterize
the interaction of bilitranslocase with anti-sequence antibodies,
obtaining the same results (Battiston et al., 1998). The ability
of BR to inhibit BSP uptake was also observed with liver slices
obtained from either human or rat liver; such inhibition was
found to overlap with that due to bilitranslocase antibodies, but
not with taurocholate, which is a substrate of OATPs but not
of bilitranslocase (Terdoslavich et al., 2012). BR was also shown
to inhibit the uptake of quercetin (a flavonoid molecule) into
cells of the vascular endothelium (cell line Ea.hy926), expressing
bilitranslocase, as assessed using antibodies (Maestro et al., 2010).
BR was also found to inhibit uptake of 2,4-Dinitrophenyl-S-
glutathione, a standard substrate of MRP1, MRP2 and MRP5, in
washed erythrocytes and their inside-out vesicles (Matsushima
et al., 2017).
Studies with Bilirubin Conjugates, Used as
Substrates or Modulators
These studies investigated themechanism(s) responsible of either
transport of conjugated BR into the bile canaliculus or their reflux
from the liver into the blood.
In rat liver sinusoidal plasma membrane vesicles, uptake
of bilirubin glucuronides has been characterized as sodium-
independent, electrogenic and competitively inhibited by both
BSP and BR (Adachi et al., 1990). Though this function has
been left without further molecular characterization, it seems that
it could be performed by OATPs expressed on the sinusoidal
membrane. In fact, an experiment using [3H]BMG in HEK293
cells, transfected with the “SLC21A6 gene” and expressing
“OATP2” protein (OATP1B1) (König et al., 2000), showed the
involvement of this liver sinusoidal membrane transporter in the
ATP-independent eﬄux to the blood of BMG and other organic
anions. Later on, the same cell system was used to show that
OATP1B1 transported [3H]BR conjugates (Cui et al., 2001).
ATP-dependent eﬄux of BR conjugates also occurs at the
sinusoidal membrane surface of hepatocytes, as shown in a study
(Lee et al., 2004) that used plasma membrane vesicles obtained
from the cell line MDCKII stably transfected with MRP3. The
data support the concept that MRP3-mediated eﬄux of bilirubin
glucuronides and other cholephilic compounds is a mechanism
underlying the reflux of bile components from the liver to the
blood, in situations of cholestasis.
Considering the ATP-dependent transporters expressed at the
canalicular side of the liver cells, one of the pioneering studies
used various plasma membrane preparations expressing human
MRP1 and MRP2 and rat Mrp2, aiming at characterizing
the ATP-dependent transport of both bilirubin mono-
glucuronide (BMG) and BDG. Furthermore, both conjugates
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were demonstrated to inhibit leukotriene transport (Jedlitschky
et al., 1997), which is mediated by the same ATP-dependent
primary active transporters, with IC50 values 0.1–0.7µM,
depending on the type of membrane preparation. A study
(Kamisako et al., 1999) using membrane vesicles prepared from
human cells transfected with either rat Mrp2 or human MRP2
provided the kinetic details of ATP-dependent transport of
BMG and BDG (Km = 0.7–0.9µM and Vmax = 255–321 pmol
min−1 mg−1 of protein). A study using sandwich-cultured
rat hepatocytes forming bile canaliculi (Nakanishi et al.,
2012) confirmed that bilirubin glucuronides could inhibit the
Mrp2-mediated secretion of a fluorescein compound in the
canaliculi, as detected by quantitative time-lapse imaging.
In Vivo Studies on Membrane Transport of
Bilirubin
Animal models with defective expression of membrane
transporters have essentially contributed to the elucidation of
the mechanisms of BR uptake into the liver, excretion into the
bile, and reflux from the liver to the blood. Table 4 lists in vivo
transport studies.
TABLE 4 | Features of included articles reporting in vivo studies.
References Species Experimental model Treatment Tissue/Biofluid Transporter Search #
Watchko et al., 1998 Mouse Mdr1−/− Single i.v. dose of bilirubin
(50mg/kg)
Whole-brain, serum P-gp 1st
Hankø et al., 2003 Rat Young adult rats Single i.v. dose of bilirubin
(50mg/kg)
Whole-brain, serum P-gp 1st
Belinsky et al., 2005 Mouse Mrp3−/− Bile duct ligation Serum Mrp3 1st
Hirouchi et al., 2005 Rat Eisai hyperbilirubinuria rats Transfection of MRP2 Serum, bile MRP2 1st
Itani et al., 2005 Rat Eisai hyperbilirubinuria rats Transfection of MRP2 Serum MRP2 4th
Chu et al., 2006 Mouse Mrp2−/− Serum, urine, bile Mrp2 1st
Mennone et al.,
2006
Mouse Mrp4−/− Bile duct ligation Serum Mrp4 1st
Narvaiza et al., 2006 Mouse Wild type mice Silencing of Abcc2 by
shRNAs
Serum Mrp2 4th
Nishiya et al., 2006 Rat Eisai hyperbilirubinuria rats Single oral dose of tienilic
acid (300mg/kg)
Serum, bile Mrp3 1st
Zelcer et al., 2006 Mouse Mrp3−/− Bile duct ligation Serum Mrp3 4th
Maher et al., 2008 Mouse Wild type mice Single i.p. dose of
perfluorodecanoic acid
(80mg/kg)
Serum Mrp3, Mrp4 4th
Zaher et al., 2008 Mouse Oatp1b2−/− Serum Oatp1b2 4th
Mennone et al.,
2010
Mouse Bcrp−/− Bile duct ligation Serum Bcrp 1st
van de Steeg et al.,
2010
Mouse Oatp1a/1b Serum, bile, urine Oatp1a1, Oatp1a4,
Oatp1a5, Oatp1a6,
Oatp1b2
4th
Vanwijngaerden
et al., 2011
Human Intensive care unit patients Serum NTCP, OATP1B1,
OATP1B3, MRP3, MRP4,
BSEP, MRP2, MDR1, MDR3
4th
Gong et al., 2011 Mouse Oatp1a1−/− and Oatp1a4−/− Serum Oatp1a1, Oatp1a4 4th
Hayashi et al., 2012 Human Ornithine transcarbamylase
deficiency patients
Treatment with
4-phenylbutyrate
Serum MRP2 1st
Scheer et al., 2012 Mouse Mrp2−/− Transfection of MRP2 Serum, urine MRP2 1st
van de Steeg et al.,
2012
Mouse (i) Oatp1a/1b−/−, Mrp3−/−,
(ii) Oatp1a/1b−/−, Mrp2−/−,
(iii) Oatp1a/1b−/−, Mrp3−/−,
Mrp2−/−
Transfection of OATP1B1,
OATP1B3 in Oatp1a/1b−/−
Serum MRP2, MRP3,
OATP1B1, OATP1B3
1st
van de Steeg et al.,
2013
Mouse Oatp1a/1b−/− Transfection of OATP1B1,
OATP1B3, OATP1A2
Serum, bile, urine OATP1A2, OATP1B1,
OATP1B3
4th
Chu et al., 2015 Monkey Cynomolgus monkeys Single oral dose of rifamycin
(18mg/kg)
Serum OATP1B1, OATP1B3 1st
Watanabe et al.,
2015
Rat Young adult rats Single i.v. injection of
rifampicin (5, 20, or
80mg/kg)
Serum rOatps, rMrp2 4th
de Waart et al., 2016 Mouse ATP11C−/− Serum Oatp1b2, Oatp1a1,
Oatp1a4
1st
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Sinusoidal Uptake of Bilirubin
Various murine models with disrupted expression of hepatic
OATP transporters have been created, serving the primary need
to assess their contribution to drug transport and interactions.
The phenotype of these murine models has been assessed, by
monitoring serum bilirubinemia, together with other biomarkers
of liver pathology. Indeed, the knockout models displayed no
sign of liver histopathology (Chen et al., 2008; Lu et al., 2008;
Zaher et al., 2008; Gong et al., 2011) and no major change
in expression of other influx or eﬄux transporters and P450
enzymes (Chen et al., 2008) or UDP-glucuronosyltransferase 1a1
(van de Steeg et al., 2010). In some cases, however, compensatory
overexpression of other SLC transporters was noted (Lu et al.,
2008).
The model mice Oatp1a1−/− and Oatp1a4−/− had normal
clinical chemistry, i.e., no elevation of serum BR, showing
that neither conjugated nor unconjugated bilirubin (UCB)
is a substrate for these transporters. By contrast, sizeable
changes in uptake and pharmacokinetics of some cholephilic
compounds, such as estradiol 17-glucuronide (E2-17G), estradiol
3-glucuronide (E2-3G), and taurocholate, but not digoxin, were
observed (Gong et al., 2011).
In rodent species, Oatp1b2 is the single ortholog that is
most similar to both OATP1B1 and OATP1B3 expressed in
human. The Oatp1b2−/− mouse exhibited significant loss of
function with respect to drug transport, such as phalloidin
and microcystin-LR (Lu et al., 2008), rifampicin, rifamycin SV,
lovastatin, simvastatin, pravastatin and cerivastatin (Chen et al.,
2008; Zaher et al., 2008). All studies reported just mild and stable
hyperbilirubinemia, mostly due to conjugated BR (Lu et al., 2008;
Zaher et al., 2008). This suggests that, under normal conditions,
Oatp1b2 mediates the reuptake of conjugated BR from the blood
into the liver.
A mice mutant (Slco1a/1b−/− mice), functionally deficient
of all 5 Slco1a (Oatp1a1,−1a4, 1a5, and−1a6) and Slco1b2
(Oatp1b2) genes, was developed to examine the joint role of
these Oatp members, expressed at the absorbing surface of liver,
intestinal and kidney cells, in drug pharmacokinetics and drug-
drug interactions (van de Steeg et al., 2010). The only effect
that loss of these proteins caused was marked hyperbilirubinemia
(>40-fold), with 95% of this increase due to conjugated BR. UCB
increased by 2.5 times, together with unconjugated bile acids (13-
fold). Though bile flow was unchanged, BR excretion was half
than in wild types. Altogether, these data are consistent with the
view that a substantial eﬄux of conjugated BR by sinusoidalMrp3
occurs, and the loss of the influx pathway caused by the cluster of
Oatp1a/1b is the main cause of the observed elevated levels of
conjugated BR in serum. However, this model left unanswered
the question regarding the mechanisms that ensure transfer of
UCB from the blood into the liver (van de Steeg et al., 2010).
When this knockout mouse model was transfected with the
human genes encoding for OATP1A2, OATP1B1 or OATP1B3,
total and conjugated BR in serum was partially (with OATP1A2)
or completely normalized (with OATP1B1 and OATP1B3) (van
de Steeg et al., 2013).
Another recent study combined both genetic studies in
humans and functional studies in mouse models (van de
Steeg et al., 2012) to describe the mechanistic basis of Rotor
syndrome (benign hereditary conjugated hyperbilirubinemia).
Using knockout mice deficient in one, two or all three
genes encoding for Oatp1a/1b, Mrp 2 and Mrp3, the authors
demonstrated the sequential involvement of Mrp3, which
promotes excretion of BR conjugates in the blood at the level
of upstream hepatocytes, and that of Oatp1a/1b, which mediates
their reuptake in the downstream hepatocytes. Thus, the plasma
bilirubin glucuronide levels were significantly increased in
knockout mice deficient of Oatp1a/1b alone or both Oatp1a/1b
and Mrp2. By contrast, in mice deficient of both Oatp1a/1b
and Mrp3 these levels markedly decreased. To strengthen
these findings and understand whether the corresponding
human proteins act in the same way, Oatp1a/1b–deficient
mice were transfected so to generate transgenic mice with
liver-specific expression of human OATP1B1 or OATP1B3. In
both models, conjugated BR levels were normalized suggesting
the reabsorption of bilirubin glucuronides by OATP1B1 and
OATP1B3. These data indicate the existence of a corresponding
liver-blood shuttling loop in humans with MRP3, OATP1B1
and OATP1B3 as key players in maintaining BR blood levels
stable.
The ATP11C-deficient mouse is a model that displays
conjugated hyperbilirubinemia and hypercholanemia, as a
consequence of the defect of this P-type ATPase that catalyzes the
exchange of membrane phospholipids, also known as flippase.
Flipping membrane phospholipids is an essential function in bile
formation. ATP11C deficiency caused decreased expression of
Oatp1b2, Oatp1a1, and Oatp1a4 (de Waart et al., 2016), thus
simulating the role of Oatp1a/1b-knock-out mice (van de Steeg
et al., 2010) and confirming that these Oatps contribute to hepatic
reuptake of conjugated BR from the blood.
Consistently with the observation that transporter-deficient
rodent models have no sign of liver pathology, except for
hyperbilirubinemia, drugs that are transported by OATP
and/or MRP transporters are expected to cause changes in
bilirubinemia, in the absence of other signs of liver toxicity.
A pharmacokinetic test done in rats with rifampicin, known
for its potent and selective inhibition of Oatp transporters
and a less potent effect on Mrp2, showed total serum bilirubin
to increase by 62.8 ± 12.2% and 78.3 ± 16.0% at 1 h after
administration of 20 and 80 mg/kg rifampicin, respectively,
and these changes were due to conjugated BR (Watanabe
et al., 2015). These results established the utility of serum
BR as a sensitive and fast-responding biomarker of drug-
transporter(s) interactions in pre-clinical studies. Nevertheless,
a thorough analysis of a human hyperbilirubinemia dataset
and the respective OATP1B1 and OATP1B3 inhibition
predictions (Kotsampasakou et al., 2017a) indicated no strong
association between OATP inhibition and hyperbilirubinemia,
either for humans or for animals (Kotsampasakou et al.,
2017b).
Excretion of Conjugated Bilirubin into the Bile
In humans, active transport of BDG in the bile is mediated by
MRP2, as proven in above-mentioned in vitro studies (Jedlitschky
et al., 1997; Kamisako et al., 1999). Mutations of this gene
are known to cause the autosomal recessive Dubin-Johnson
syndrome with mild conjugated hyperbilirubinemia. The Eisai
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hyperbilirubinemic rat (Kawaguchi et al., 1994) has a hereditary
loss of Mrp2 function and is therefore an experimental model of
the Dubin-Johnson syndrome.
In Eisai hyperbilirubinemic rats, i.v. injection of
recombinant adenoviruses containing MRP2 resulted in
the simultaneous expression of MRP2 at the hepatic canalicular
membrane, recovery of normal biliary excretion of DBSP
(dibromosulfophtalein) and a marked decrease of serum direct
(conjugated) BR (Hirouchi et al., 2005). Similar results were
obtained using a different transfecting approach consisting in
an MRP2 protein-expression plasmid vector, wrapped with the
hemagglutinating virus of Japan envelope protein. One day
after the i.v. injection of this kit, the expression of MRP2 in the
liver canalicular membrane of Eisai hyperbilirubinemic rats was
normalized. This entailed normalization of expression levels
of Oatp1 and Oatp2 that are downregulated in this rat strain
and of MRP3 that is upregulated. As a result, serum total and
conjugated BR dropped within 24 h post-transfection (Itani et al.,
2005).
Adenovirus was also used as a vector to transfect mice with
short hairpin RNAs targeting Mrp2 (Abcc2). This treatment
caused marked down-regulation of Abcc2 mRNA and a marked
increase of total serum BR. These effects lasted several days,
until the injected shRNAs were degraded (Narvaiza et al.,
2006).
In Mrp2−/− mice, the biliary excretion rate of BDG was
about half than in wild types (Chu et al., 2006). However,
in these knockout mice, no other eﬄux transporter, e.g., the
sinusoidal eﬄux pump Mrp3, was activated by gene induction.
Therefore, this mouse transgenic line corresponds to neither the
Dubin-Johnson syndrome nor the Eisai hyperbilirubinemic rat.
However, transfection of humanMRP2 inMrp2−/−mice (Scheer
et al., 2012) led to normalization of conjugated BR levels in both
plasma and urine.
A study (Hayashi et al., 2012) showed that the drug
4-phenylbutyrate (4PBA) increased the cell surface expression
and transport function of MRP2 in the MRP2-MDCKII cell
line and of Mrp2 in the rat liver, without significantly changing
the MRP2/Mrp2 mRNA level. This drug is used to manage
enzyme defects of urea production, as in the syndrome known
as Ornithine Transcarbamylase Deficiency (OTCD), in order
to provide an alternative pathway for the excretion of excess
nitrogen. Indeed, the same study observed that in OTCD
patients, 4PBA increased hepaticMRP2 expression and decreased
total bilirubinemia.
Another primary active transporter expressed at the
canalicular side of the hepatocyte plasma membrane is the
Breast cancer resistance protein (Bcrp). In Bcrp-knockout
mice, no changes in serum BR were detected, showing that
this protein has no relevant role in BDG excretion (Mennone
et al., 2010). In these models, bile-duct ligation, which induces
adaptive up-regulation of apical Mdr1 (P-gp) or sinusoidal
Mrp4, did not change Bcrp expression nor serum BR. Partly
different findings have been reported in an independent study
(Vlaming et al., 2009), which demonstrated that Bcrp-knockout
mice showed significant hyperbilirubinemia, mostly due
to UCB.
Reflux of Conjugated Bilirubin into the Blood in
Molecular Defects of Biliary Excretion
In case of biliary obstruction or Dubin-Johnson syndrome, the
serum levels of conjugated BR increase. The identification of
Mrp3 as the main sinusoidal membrane transporter responsible
for the reflux of conjugated BR into the blood has been
demonstrated by using either knockout mice models or by
finding upregulated Mrp3 expression as a side-effect of a diuretic
drug, as a toxic effect of chemicals used in industry, or in critically
ill patients.
Loss of either Mrp3 or Mrp4 in (−/−) null mutant mouse
colonies caused no change of serum BR as compared to wild
types. However, common bile duct ligation for 3 (Belinsky et al.,
2005; Zelcer et al., 2006) or 7 days (Mennone et al., 2006) shed
light on the different roles of these eﬄux pumps in experimental
cholestasis. In Mrp3−/− mice, a substantial decrease of serum
conjugated BR levels was shown, as compared with controls, but
levels of serum bile acids remained unchanged (Belinsky et al.,
2005; Zelcer et al., 2006). By contrast, in Mrp4−/− mice, serum
levels of total BR did not change, whereas a 5-fold decrease of
serum bile acids was observed as compared with wild type mice
(Mennone et al., 2006). These findings suggested that that Mrp4
is a sinusoidal eﬄux transporter for bile acids, but not for bile
pigments.
The same conclusion about the function of Mrp3 in
promoting eﬄux of conjugated BR has been reached in studies
aiming at clarifying the mechanism of toxicity of the diuretic
drug tienilic acid (Nishiya et al., 2006). If administered to
Eisai hyperbilirubinemic rats, a dose-dependent increase of total
bilirubinemia coupled with up-regulation of (mRNA) Mrp3 and
heme oxygenase-1 was recorded.
Treating mice with perfluorinated carboxylic fatty acids
(PCFA) induced the hepatic expression of both Mrp3 and Mrp4,
which increased levels of conjugated bilirubin and total bile
acids in serum. Induction was mediated by activation of both
peroxisome proliferator–activated receptor alpha (PPARα) and
NF-E2-related factor-2 (Nrf2) (Maher et al., 2008).
Up-regulation of MRP3 and MRP4 on the sinusoidal
membrane of hepatocytes was observed in post-mortem biopsies,
taken from long-term critically ill patients (Vanwijngaerden
et al., 2011). Liver biopsies revealed histological aspects of
cholestasis. Pre-mortem blood samples showed predominantly
conjugated hyperbilirubinemia and hypercholanemia. These
findings consistently underline the role of these transporters in
mediating active eﬄux of cholephilic anions into the blood.
The Molecular Barrier for Bilirubin Transport into the
Brain
At the level of the blood-brain barrier, P-glycoprotein has been
shown to play a role in protecting the brain from accumulation
of BR, as demonstrated by in vitro experiments reported above.
The first study tested the role of P-glycoprotein in limiting the
brain accumulation of BR. Thus, wild type and Mdr1a(−/−) null
mutant mice received an intra-venous bolus of BR and their brain
BR contents weremeasured 10 and 60min after the infusion. Null
mutants nearly doubled their brain BR, as compared to wild types
(Watchko et al., 1998). This study contributed to demonstrating
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that P-glycoprotein could transport BR as an endogenous
substrate. This observation was confirmed in experiments with
wild type Sprague-Dawley rats (Hankø et al., 2003). Their brain-
to-plasma BR ratio measured after an i.v. bolus of BR was
higher if it was preceded by a short (10min) infusion with
P-glycoprotein blockers, like propanolol, verapamil, ceftriaxone,
and rifampin.
DISCUSSION
Outcome of the Search Strategy
The most unexpected outcome of having sourced PubMed by a
multiphase search approach was the missing retrieval of at least 6
articles, tagged with correct MeSH terms.
These limitations can be overtaken by manual search, but
wandering in the literature is subjective and inefficient. Another
option might be the use of a different query, with “transport”
instead of “transporter.” However, queries should straightly
reflect the goal(s) of the systematic review. This review was
meant at creating a list of BR membrane transporters, with
no interest in articles dealing with other biological transport
phenomena, such as albumin transport of BR in the blood or
non-catalyzed diffusion of BR through biological membranes.
Another implication of using generic query terms is that the
burden of screening and eligibility checks may obfuscate the
operational value of the automatic search.
We have also noticed articles that did not list “bilirubin” as
keyword or MeSH term, in spite of reporting results about its
analysis, which caused them to be out of the list of included
papers. Authors should therefore be aware of a proper choice of
descriptors of their works.
Features of Bilirubin Membrane Transport
Studies
Table 5 presents a synopsis of the outputs of our systematic
review. Experimental models with increasing levels of structural
and functional complexity (row 1) have been exploited to
characterize the transporters (column 1) for BR and its
conjugates. Discovery started historically with the most reductive
experimental approach, i.e., BR binding assays on an isolated
protein or binding/transport in plasmamembrane vesicles. In the
last decade, the development of knockout/knockin rodentmodels
has enabled to investigate the functional role of membrane
transporters in vivo.
Regarding the top 2 questions asked, i.e., “what transporters
. . . ?” and “what experimental models . . . ?”, the extent or depth
of knowledge about the listed membrane transporters can be all
in all scored by the number of experimental models exploited to
characterize a given transporter. Thus, rather than scoring single
articles, we propose here to score the reproducibility of results
on a given BR membrane transporter in multiple experimental
approaches.
The champion in this review is the canalicular primary
active transporter MRP2, investigated at 4 levels of biological
complexity (i.e., vesicles, cells, in vivo rodent models and in
humans) in 13 distinct studies. Next is the OATP cluster of
sinusoidal transporters, investigated at 3 levels in 9 studies.
Third is the sinusoidal transporter bilitranslocase, investigated
at 3 levels in 5 studies. The “spillover” effect of the high
intensity of MRP2 studies on knowledge related to the role of
basolateral eﬄux transporters MRP3 and MRP4 benefited from
the availability of genetically modified rodent models.
Membrane Transporters for Bilirubin and
Its Conjugates
What Do We Know Now about Bilirubin Membrane
Transporters?
Table 6 lists the transporters studied in the 44 articles included
in this review. With the exception of OABP and BBBP, all are
annotated in the Transporter Classification Database (TCDB)
(Saier et al., 2016). Of these, all but bilitranslocase have a
gene name assigned by HUGO Gene Nomenclature Committee
(HGNC) (Gray et al., 2015) and/or the Rat Genome Database
(Shimoyama et al., 2015) and the Mouse Genome Database
(Blake et al., 2017).
According to the TCDB, BR transporters are either
Electrochemical potential-driven (coded as 2.A.) or Primary
active (coded as 3.A.). According to HGNC, they are either solute
carriers (coded as SLC) or ATP-binding cassette transporters
(coded as ABC).
Primary Active Transporters Mediate ATP-Dependent
Cellular Efflux of Both Conjugated and Unconjugated
Bilirubin
These transporters have an intracellular ATP hydrolase
domain and a transport site for the unidirectional substrate
translocation. Their transport substrates are chemically
heterogeneous, including many drugs. It is established that
MRP2 determines transport of conjugated BR from the liver
into the bile at the canalicular membrane. In case of cholestasis,
up-regulation of sinusoidal MRP3 determines eﬄux of the
conjugated pigment from the liver into the blood. At the level
of the placental trophoblast and the blood-brain barrier, MDR1
or MRP1 mediate eﬄux of UCB toward the maternal or general
circulation, respectively.
Electrochemical Potential-Driven Transporters
Mediate Bi-Directional Transport of Bilirubin and Its
Conjugates
These transporters transfer solutes up to their electrochemical
equilibrium between membrane-separated compartments. In the
liver, they are expressed at the basolateral membrane domain.
They have wide substrate specificity and transport drugs as well.
Transporters of Conjugated Bilirubin
OATP1B1 and OATP1B3 transport BMG and BDG from the
blood into the liver. In vivo studies with transporter-deficient
mice lines have demonstrated a major role of OATP1B1/1B3 (van
de Steeg et al., 2010, 2012) in promoting re-uptake of conjugated
bilirubin from the blood.
Transporters of Bilirubin
Less clear is the capacity of OATPs to mediate uptake of UCB
from the blood into the liver. In vitro uptake studies have
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TABLE 5 | Synopsis of the experimental models used to study membrane transporters for bilirubin and its conjugates.
Transporter Protein Vesicles Cells Tissues Rodents in vivo Primates in vivo
Unknown Adachi et al., 1990
Organic Anion
Binding Protein
Wolkoff and
Chung, 1980
BSP/bilirubin
binding protein
Stremmel et al., 1983 Stremmel and Diede,
1990
Bilitranslocase Passamonti and
Sottocasa, 1990;
Passamonti et al., 1997
Passamonti et al.,
2005b; Maestro et al.,
2010
Terdoslavich et al.,
2012
OATP1A2,
OATP1B1
/OATP1B,
Oatp1b2
König et al., 2000; Cui
et al., 2001; Briz et al.,
2003; Wang et al.,
2003; Chu et al., 2015
Chen et al., 2008; Lu et al.,
2008; Zaher et al., 2008;
van de Steeg et al., 2010,
2012, 2013; Watanabe
et al., 2015; de Waart et al.,
2016
Vanwijngaerden
et al., 2011; Chu
et al., 2015
MRP1, Mrp1 Jedlitschky et al., 1997;
Rigato et al., 2004;
Matsushima et al.,
2017
Pascolo et al., 2001;
Calligaris et al., 2006
Mdr1/P-gp Watchko et al., 1998;
Hankø et al., 2003;
Mennone et al., 2010
MRP2, Mrp2 Jedlitschky et al., 1997;
Kamisako et al., 1999;
Rigato et al., 2004;
Matsushima et al.,
2017
Nakanishi et al., 2012;
Matsushima et al.,
2017
Hirouchi et al., 2005; Itani
et al., 2005; Chu et al.,
2006; Narvaiza et al., 2006;
Scheer et al., 2012; van de
Steeg et al., 2012;
Watanabe et al., 2015
Hayashi et al.,
2012
Oatp1a1 /Oatp1a4 van de Steeg et al., 2010;
Gong et al., 2011; de Waart
et al., 2016
Bcrp Mennone et al., 2010
MRP3, Mrp3 Lee et al., 2004 Belinsky et al., 2005; Nishiya
et al., 2006; Zelcer et al.,
2006; Maher et al., 2008;
van de Steeg et al., 2012
Vanwijngaerden
et al., 2011
Mrp4 Mennone et al., 2006;
Maher et al., 2008
Vanwijngaerden
et al., 2011
MRP5 Matsushima et al.,
2017
Matsushima et al.,
2017
The transporters are listed according the publication date of articles first reporting relevant studies.
produced contradicting results, with evidence both in favor (Cui
et al., 2001; Briz et al., 2003) and against (Pascolo et al., 2001;
Wang et al., 2003) the hypothesis that UCB is a substrate of
certain OATPs.
Population studies showed that single-nucleotide
polymorphisms of either the gene SLCO1B1 or the gene
SLC1B3 are associated with mild elevations of conjugated BR
(Zhang et al., 2007; Sanna et al., 2009) or UCB (Sanna et al.,
2009) in serum, respectively.
A deeper study with transgenic mice expressing
OATP1B1/1B3/1A2 (van de Steeg et al., 2013) provided
evidence in support of the concept that OATPs play a limited
role in uptake of UCB into the liver.
Also, studies on the ontogeny of hepatic drug transporters
(Mooij et al., 2014) indicated that the mRNA expression of
OATP1B1 and OATP1B3 is 500–600-fold lower in human
neonates than in adults. Considering that in neonates there is
a rise of UCB in serum, it may be suggested that alternative
membrane transporters for BR should be responsible for
bilirubin uptake into the liver.
Furthermore, analyses of hepatic toxicity in humans and
animals did not indicate strong association between OATP
inhibition and hyperbilirubinemia, neither for humans nor for
animals (Kotsampasakou et al., 2017b).
This does not mean that OATPs have little to do with
membrane transport of bile pigments. First, their apparent
limited role in determining UCB levels in serum might just
indicate that BR and BDG are mutually competing for transport
by OATPs, with prevailing affinity and occupancy of BDG in
the transporter active site. Further clues might be found in
other domains of the natural sciences. Two studies have shown
that expression of OATP1B3 in the hen’s oviduct and the shell
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TABLE 6 | Membrane transporters of bilirubin and its conjugates.
Acronym Organism Names and synonyms TCDB RGD/MGI HGNC Bilirubin
molecule
OABP Rat Organic Anion Binding protein Bilirubin
BBBP Rat BSP/bilirubin Binding protein Bilirubin
BTL Rat, human Bilitranslocase. Bilirubin transporter 2.A.65.1.1 Bilirubin
Oatp1a1 Mouse, rat Organic anion-transporting polypeptide 1a1. Solute carrier organic
anion transporter family, member 1a1; Oatp1, Oatp1a1, Slc21a1.
2.A.60.1.1 Slco1a1 SLCO1A2 Conjugated
bilirubin;
bilirubin
Oatp1a4 Mouse, rat Organic anion-transporting polypeptide 1a4. Solute carrier organic
anion transporter family, member 1a4; Oatp1a4, Oatp2, Slc21a5;
AI785519
2.A.60.1.6 Slco1a4 SLCO1A2 Conjugated
bilirubin;
bilirubin
Oatp1a5 Mouse, rat Organic anion-transporting polypeptide 1a5. Solute carrier organic
anion transporter family, member 1a5; Oatp3, Slc21a7
Slco1a5 SLCO1A2 Conjugated
bilirubin;
bilirubin
Oatp1a6 Mouse Organic anion-transporting polypeptide 1a6. Solute carrier organic
anion transporter family, member 1a6; 4930422F19Rik, Oatp5,
organic anion-transporting polypeptide, Slc21a13
2.A.60.1.25 Slco1a6 SLCO1A2 Conjugated
bilirubin;
bilirubin
Oatp1b2 Mouse, rat Organic anion-transporting polypeptide 1b2. Solute carrier organic
anion transporter family, member 1b2; OATP2; Oatp4; lst-1;
OATP-C; mlst-1; Oatp1b2; Slc21a6; Slc21a10; 7330442B20Rik
Slco1b2 SLCO1B1,
SLCO1B3,
SLCO1B7
Conjugated
bilirubin
OATP1B1 Human Organic anion-transporting polypeptide 1B1. Solute carrier
organic anion transporter family member 1B1; LST1; HBLRR;
LST-1; OATP2; OATPC; OATP-C; OATP1B1; SLC21A6
2.A.60.1.5 Slco1b2 SLCO1B1 Conjugated
bilirubin;
bilirubin
OATP1B3 Human Organic anion-transporting polypeptide 1B3. Solute carrier
organic anion transporter family member 1B3; LST3; HBLRR;
LST-2; OATP8; OATP-8; OATP1B3; SLC21A8; LST-3TM13
2.A.60.1.12 Slco1b2 SLCO1B3 Conjugated
bilirubin;
bilirubin
OATP1A2 Human Organic anion-transporting polypeptide 1A2. Solute carrier organic
anion transporter family member 1A2; OATP; OATP-A; OATP1A2;
SLC21A3
2.A.60.1.14 SLCO1A2 Conjugated
bilirubin;
bilirubin
Mdr1a Rat, mouse Mdr1a, mdr-3, MDR3, Evi32, multiple drug resistant 1a,
P-glycoprotein, Pgp, P-gp, Pgy3, Pgy-3
Abcb1a ABCB1 Bilirubin
MDR1 Human CLCS; MDR1; P-GP; PGY1; ABC20; CD243; GP170 3.A.1.201.1 ABCB1 Bilirubin
Mrp1, MRP1 Rat, mouse,
human
ATP-binding cassette sub-family C (CFTR/MRP) member 1a; MRP,
Mrp1, multidrug resistance protein 1; Leukotriene C(4) (LTC4)
transporter
3.A.1.208.8 Abcc1 ABCC1 Bilirubin
Mrp2, MRP2 Rat, mouse,
human
ATP-binding cassette, sub-family C (CFTR/MRP), member 2;
Cmoat, Mrp2, multidrug resistance protein 2
3.A.1.208.2 Abcc2 ABCC2 Conjugated
bilirubin
Mrp3, MRP3 Rat, mouse,
human
ATP-binding cassette, sub-family C (CFTR/MRP), member 3,
MOAT-D, Cmoat2, multidrug resistance protein 3
3.A.1.208.9 Abcc3 ABCC3 Conjugated
bilirubin
Mrp4, MRP4 Rat, mouse,
human
ATP-binding cassette sub-family C member 4;
(MRP/cMOAT-related ABC transporter; Multi-specific organic
anion transporter B (MOAT-B)
3.A.1.208.7 Abcc4 ABCC4 None
Mrp5, MRP5 Rat, mouse,
human
ATP-binding cassette sub-family C member 5; Multi-specific
organic anion transporter C (MOAT-C); MRP5; SMRP; ABC33;
MOAT-C.
3.A.1.208.15 Abcc5 ABCC5 Bilirubin
Bcrp1, BCRP Mouse Breast cancer resistance protein 1 homolog; Urate exporter 3.A.1.204.2 Abcg2 ABCG2 None
Transporters are identified by codes of the TCDB, Transporter Classification Database; RGD, The Rat Genome Database; MGI, The Mouse Genome Database; HGNC, The HUGO Gene
Nomenclature Committee.
gland confers the phenotype of depositing blue-shelled eggs,
as a result of inclusion of biliverdin in the shell (Wang et al.,
2013; Wragg et al., 2013). It may be therefore speculated that
OATP1B3 may take part in the rapid and trans-compartmental
(blood-liver) redox equilibrium of BR/biliverdin. The occurrence
of the BR/biliverdin pair in human serum could be detected by
advanced analytics (Martelanc et al., 2016).
Hence, UCB uptake into the liver must certainly result
from redundancy and complementation of multiple membrane
transporters, as it is for enzymes (Pandya et al., 2014). The
synopsis in Table 5 shows indeed pieces of redundancy.
The membrane transporter bilitranslocase (BTL) has been
characterized as a BR transporter in plasma membrane vesicles,
where it has been kinetically characterized by the electrogenic
BSP transport assay (Passamonti et al., 2010), with UCB as a
competitive inhibitor (Ki = 0.11µM) (Passamonti et al., 2005a).
Time-dependent inhibition by either protein reagents or affinity-
purified, anti-sequence antibodies showed that bilitranslocase has
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at least two apparent, high-affinity BR binding sites (Ki = 0.3
and 2 nM, respectively), located on extracellular domains of
the protein and both targeted by 2 different anti-sequence
antibodies (Battiston et al., 1998; Passamonti et al., 2005a). One
of these antibodies inhibited cellular uptake of BR, added at
50 nM in an albumin-free solution (Passamonti et al., 2005b).
It should be stressed that the electrogenic BSP transport
assay measures the activity of a BSP transporter completely
different from any other SLC transporter, as assessed by an
extensive functional characterization of its competitive and non-
competitive inhibitors (Zuperl et al., 2011) and as confirmed by
BSP uptake tests in rat and human liver slices (Terdoslavich et al.,
2012).
The troubled question about this transporter is its gene, which
has not yet been characterized, as well as its mRNA, which
corresponds to a large segment of the anti-sense strand of the
gene that encodes for caeruloplasmin (Battiston et al., 1998;
Passamonti et al., 2009) and follows therefore the unpredictable
fate of sense-antisense RNA pairs. Yet, by applying a package
of highly sophisticated computational approaches (Venko et al.,
2017), the bilitranslocase primary structure was turned into a
3D membrane protein model that comprises 4 trans-membrane
domains (Roy Choudhury et al., 2013), 2 of which interact and
both are able to make a synergistic kink in the middle of the
membrane, providing a theoretical structural requirement for
substrate translocation (Roy Choudhury et al., 2015).
Both OATP1B1 (Wang et al., 2005; Mandery et al., 2012) and
bilitranslocase (Passamonti et al., 2002; Karawajczyk et al., 2007)
have the demonstrated capacity to transport dietary flavonoids
that, by transport competition, may intermittently interfere with
the fine blood-liver equilibrium of BR. It is obvious therefore
that multiple, membrane transporters for UCB must coexist and
concur to rapid and rate-unlimited BR uptake into the liver. It
may be that the other BR-binding proteins in the list of Table 3,
i.e., OABP (Wolkoff, 2014) and BBBP (Brandoni et al., 2012), or
additional ones yet to discover, may contribute to BR uptake into
the liver.
CONCLUSIONS
This is the first systematic review of experimental studies on
membrane transporters for BR and its conjugates. We selected
44 articles reporting in vitro and in vivo studies published
from 1980 to July 2017. They reported about 11 electrochemical
potential-driven and 8 primary active membrane transporters.
Paradoxically, the remarkable advancements in this field have
only confirmed the elusive mechanism(s) enabling UCB to
diffuse into the liver as if no cellular boundary existed.
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